Total Payments
$297,939
2024 Payments
$6,611
Companies
27
Transactions
517
Medicare Patients
116
Medicare Billing
$12,912
Payment Breakdown by Category
Consulting$161,078 (54.1%)
Other$55,067 (18.5%)
Research$21,988 (7.4%)
Education$21,672 (7.3%)
Travel$19,103 (6.4%)
Food & Beverage$18,822 (6.3%)
Gifts$210.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $161,078 | 42 | 54.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,072 | 25 | 15.8% |
| Unspecified | $21,988 | 6 | 7.4% |
| Education | $21,672 | 20 | 7.3% |
| Travel and Lodging | $19,103 | 54 | 6.4% |
| Food and Beverage | $18,822 | 365 | 6.3% |
| Honoraria | $6,000 | 1 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,995 | 1 | 0.7% |
| Gift | $210.00 | 3 | 0.1% |
Payments by Type
General
$275,951
511 transactions
Research
$21,988
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $94,169 | 152 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $53,363 | 82 | $0 (2024) |
| GENZYME CORPORATION | $33,217 | 48 | $0 (2024) |
| Biogen, Inc. | $30,594 | 108 | $0 (2023) |
| Genentech USA, Inc. | $23,417 | 30 | $0 (2023) |
| F. Hoffmann-La Roche AG | $11,302 | 10 | $0 (2024) |
| TG Therapeutics, Inc. | $10,334 | 6 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $10,274 | 17 | $0 (2024) |
| Genentech, Inc. | $7,472 | 8 | $0 (2022) |
| Horizon Therapeutics plc | $7,424 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,611 | 20 | EMD Serono, Inc. ($3,820) |
| 2023 | $44,338 | 45 | EMD Serono, Inc. ($25,000) |
| 2022 | $21,201 | 32 | EMD Serono, Inc. ($6,030) |
| 2021 | $49,659 | 64 | Novartis Pharmaceuticals Corporation ($15,061) |
| 2020 | $21,184 | 28 | EMD Serono, Inc. ($8,332) |
| 2019 | $43,597 | 70 | Biogen, Inc. ($8,714) |
| 2018 | $45,640 | 97 | EMD Serono, Inc. ($19,621) |
| 2017 | $65,708 | 161 | EMD Serono, Inc. ($20,407) |
All Payment Transactions
517 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $29.44 | General |
| Category: Neurology | ||||||
| 12/09/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,170.96 | General |
| 12/09/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $580.68 | General |
| 12/09/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $169.29 | General |
| 12/06/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $136.56 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $56.37 | General |
| Category: Rare Disease | ||||||
| 09/25/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| 08/22/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $111.61 | General |
| Category: Immunology | ||||||
| 07/30/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $115.16 | General |
| 07/26/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $34.16 | General |
| Category: Neurology | ||||||
| 07/23/2024 | Sandoz Inc. | — | Food and Beverage | In-kind items and services | $40.21 | General |
| 07/11/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $105.82 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $911.14 | Research |
| Study: One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $707.93 | Research |
| Study: One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial • Category: Immunology | ||||||
| 05/08/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $104.13 | General |
| 05/02/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $112.48 | General |
| Category: Immunology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $378.00 | Research |
| Study: One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 03/01/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $72.89 | General |
| Category: Rare Disease | ||||||
| 03/01/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $39.02 | General |
| 02/29/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $55.03 | General |
| 12/07/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Neurology | ||||||
| 10/26/2023 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $68.01 | General |
| Category: Neurology | ||||||
| 09/27/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,294.00 | General |
| 09/27/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $823.50 | General |
| 09/27/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $130.07 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| KESIMPTA Study Related Review Article Writing Support | Novartis Pharmaceuticals Corporation | $11,191 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $8,700 | 1 |
| One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,289 | 2 |
| One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial | F. Hoffmann-La Roche AG | $707.93 | 1 |
| A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | GENZYME CORPORATION | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 43 | 47 | $16,523 | $4,903 |
| 2020 | 2 | 73 | 84 | $28,106 | $8,009 |
Total Patients
116
Total Services
131
Medicare Billing
$12,912
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 19 | $8,151 | $2,785 | 34.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 25 | 28 | $8,372 | $2,117 | 25.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 52 | 61 | $18,239 | $5,418 | 29.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 21 | 23 | $9,867 | $2,591 | 26.3% |
About Dr. Kottil Rammohan, MD
Dr. Kottil Rammohan, MD is a Neurology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619051018.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kottil Rammohan, MD has received a total of $297,939 in payments from pharmaceutical and medical device companies, with $6,611 received in 2024. These payments were reported across 517 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($161,078).
As a Medicare-enrolled provider, Rammohan has provided services to 116 Medicare beneficiaries, totaling 131 services with total Medicare billing of $12,912. Data is available for 2 years (2020–2021), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Miami, FL
- Active Since 10/24/2006
- Last Updated 06/23/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1619051018
Products in Payments
- Mavenclad (Biological) $39,091
- OCREVUS (Biological) $31,730
- KESIMPTA (Drug) $21,324
- AUBAGIO (Drug) $18,550
- ARZERRA (Drug) $10,110
- MAYZENT (Drug) $9,053
- LEMTRADA (Drug) $8,048
- UPLIZNA (Drug) $7,424
- Evobrutinib $6,900
- Non-Covered Product (Drug) $5,378
- Soliris (Drug) $4,368
- Ocrevus (Biological) $2,227
- TECFIDERA (Drug) $1,745
- GILENYA (Drug) $1,603
- TYSABRI (Biological) $1,065
- Mavenclad (Drug) $606.44
- Rebif (Biological) $454.45
- SOLIRIS (Drug) $362.01
- MAVENCLAD (Drug) $333.54
- VUMERITY (Drug) $232.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Miami
Dr. Diego Torres-Russotto, Md, MD
Neurology — Payments: $724,144
Neurology $724,144
Flavia Nelson, M.d, M.D
Neurology — Payments: $413,699
Neurology $413,699
Dr. Andrew Lerman, M.d, M.D
Neurology — Payments: $399,026
Neurology $399,026
Dr. Brad Herskowitz, M.d, M.D
Neurology — Payments: $301,062
Neurology $301,062
Carlos Ramirez-Calderon, M.d, M.D
Neurology — Payments: $202,041
Neurology $202,041
Alberto Pinzon Ardila, Md, MD
Neurology — Payments: $161,553
Neurology $161,553